Lexaria Bioscience (LEXX) Share-based Compensation (2010 - 2026)

Lexaria Bioscience has disclosed Share-based Compensation across 16 years of filings, most recently posting $74895.0 for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $74895.0, down 55.21% year-over-year; the trailing twelve-month figure through Feb 2026 was $742650.0 (up 5.35% YoY), and the FY2025 annual result was $859494.0, up 74.61% from the prior year.
• Share-based Compensation came in at $74895.0 for Q1 2026 at Lexaria Bioscience, roughly flat from $74895.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $470136.0 in Q2 2025 to a low of -$241610.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $81446.0 (2023), against an average of $102764.4.
• Across the five-year window, Share-based Compensation tumbled 158.93% in 2022 and jumped 901.76% in 2024, its largest moves.
• Lexaria Bioscience's Share-based Compensation stood at $68776.0 in 2022, then retreated by 21.55% to $53953.0 in 2023, then jumped by 84.26% to $99415.0 in 2024, then retreated by 24.66% to $74895.0 in 2025, then changed by 0.0% to $74895.0 in 2026.
• The last three Share-based Compensation figures came in at $74895.0 (Q1 2026), $74895.0 (Q4 2025), and $122724.0 (Q3 2025), per Business Quant data.